Tiange Yu
Tiange Yu has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Jazmine S. Mateus
Genesis Research Group, Hoboken, New Jersey, United States
3 shared publications - Kathleen Michelle Andersen
Pfizer Inc., New York, New York, United States
3 shared publications Anan Zhou
Real-World Evidence, Genesis Research Group , Hoboken, NJ 07030
2 shared publications- Laura Puzniak
Merck & Co., Inc., Kenilworth, New Jersey
2 shared publications - Santiago Manuel Cayetano Lopez
Pfizer Inc
2 shared publications Xin Zhao
Genesis Research Group
2 shared publications
Latest Publications
- Open Access
- 11 August 2026
- Published by Taylor & Francis in Journal of Medical Economics
- Vol. 29 (1) , 2135-2149
Real-world all-cause healthcare resource utilization and costs among patients with interstitial cystitis/bladder pain syndrome in the United States
Interstitial cystitis/bladder pain syndrome (IC/BPS) is a chronic, heterogeneous condition within the broader definition of urologic chronic pelvic pain syndrome [1,2]. It is diagnosed by exclusion...
- 11 August 2026
- Published by Taylor & Francis in Journal of Medical Economics
- Vol. 29 (1) , 2135-2149
Open AccessReal-world all-cause healthcare resource utilization and costs among patients with interstitial cystitis/bladder pain syndrome in the United States
Interstitial cystitis/bladder pain syndrome (IC/BPS) is a chronic, heterogeneous condition within the broader definition of urologic chronic pelvic pain syndrome [1,2]. It is diagnosed by exclusion...
- Open Access
Interim BNT162b2 LP.8.1-adapted COVID-19 Vaccine Effectiveness among Non-Immunocompromised Adults ≥65 years of age in California and Louisiana, August–December 2025
Evidence on vaccine effectiveness (VE) of 2025-26 COVID-19 vaccines is limited. We estimated VE of BNT162b2 LP.8.1-adapted vaccine among non-immunocompromised adults ≥65 years through December 2025 using linked claims and immunization registry data from two U.S. states. VE against COVID-19-related ED/UC encounters was 48% (95% CI:19, 66).
Open AccessInterim BNT162b2 LP.8.1-adapted COVID-19 Vaccine Effectiveness among Non-Immunocompromised Adults ≥65 years of age in California and Louisiana, August–December 2025
Evidence on vaccine effectiveness (VE) of 2025-26 COVID-19 vaccines is limited. We estimated VE of BNT162b2 LP.8.1-adapted vaccine among non-immunocompromised adults ≥65 years through December 2025 using linked claims and immunization registry data from two U.S. states. VE against COVID-19-related ED/UC encounters was 48% (95% CI:19, 66).
- Open Access
- 13 November 2025
- Published by Oxford University Press (OUP) in American Journal of Epidemiology
- Vol. 195 (2) , 596-601
Enhancing COVID-19 vaccine effectiveness evidence generation using tokenized immunization registries
Purpose: To describe a novel data ecosystem and quantify improvements in documented COVID-19 vaccine uptake using closed claims data and state vaccine registries. Methods: De-identified data from administrative claims were linked via tokenization to state vaccine registry data from two states with mandatory vaccine reporting. COVID-19 vaccine uptake in claims alone versus supplemented with registry data was measured separately for original wildtype, BA.4/5-adapted bivalent, and XBB.1.5-adapted formulations. Results: There were over 9 million individuals included in each formulation distribution study period. Using claims data alone versus with additional state registry data, 20% versus 57% of individuals had documented receipt of a primary wildtype series (≥2 doses of two-dose or ≥ 1 of single-dose series), 7% versus 10% BA.4/5-adapted bivalent, and 6% versus 8% XBB.1.5-adapted COVID-19 vaccine. Most claims-based vaccination events were captured with drug, rather than procedure, codes. Individuals with Medicaid-based insurance were less likely to be captured as vaccinated in claims data. Conclusions: The addition of state vaccine registries increased COVID-19 vaccine capture by 182% for primary wildtype series, 41% BA.4/5-adapted bivalent, and 38% XBB.1.5-adapted formulations. Tokenization of claims data to vaccine registries presents an opportunity for more accurate estimates of vaccine uptake and effectiveness than claims data alone.
- 13 November 2025
- Published by Oxford University Press (OUP) in American Journal of Epidemiology
- Vol. 195 (2) , 596-601
Open AccessEnhancing COVID-19 vaccine effectiveness evidence generation using tokenized immunization registries
Purpose: To describe a novel data ecosystem and quantify improvements in documented COVID-19 vaccine uptake using closed claims data and state vaccine registries. Methods: De-identified data from administrative claims were linked via tokenization to state vaccine registry data from two states with mandatory vaccine reporting. COVID-19 vaccine uptake in claims alone versus supplemented with registry data was measured separately for original wildtype, BA.4/5-adapted bivalent, and XBB.1.5-adapted formulations. Results: There were over 9 million individuals included in each formulation distribution study period. Using claims data alone versus with additional state registry data, 20% versus 57% of individuals had documented receipt of a primary wildtype series (≥2 doses of two-dose or ≥ 1 of single-dose series), 7% versus 10% BA.4/5-adapted bivalent, and 6% versus 8% XBB.1.5-adapted COVID-19 vaccine. Most claims-based vaccination events were captured with drug, rather than procedure, codes. Individuals with Medicaid-based insurance were less likely to be captured as vaccinated in claims data. Conclusions: The addition of state vaccine registries increased COVID-19 vaccine capture by 182% for primary wildtype series, 41% BA.4/5-adapted bivalent, and 38% XBB.1.5-adapted formulations. Tokenization of claims data to vaccine registries presents an opportunity for more accurate estimates of vaccine uptake and effectiveness than claims data alone.
- Open Access
2024-2025 BNT162b2 COVID-19 vaccine effectiveness in non-immunocompromised adults: mid-season estimates from vaccine registries in two states linked to administrative claims
Background: Data are limited on 2024-2025 BNT162b2 COVID-19 vaccine effectiveness (VE). Methods: Retrospective cohort study among non-immunocompromised adults from August 22, 2024 (“index”) to December 31, 2024, among residents of California or Louisiana continuously enrolled in health insurance plans reporting to HealthVerity for ≥1 year prior to index. Receipt of 2024-2025 BNT162b2 COVID-19 vaccine was defined using state vaccine registries with health insurance claims, using a time-varying exposure definition. VE against COVID-19-associated hospital admissions was estimated as (1-hazard ratio), using adjusted Cox proportional hazards models with 95% confidence intervals (CI). Results: Overall, 6,900,361 individuals met selection criteria for the study. By the end of follow-up (median 4.4 months), 325,362 (4.7%) had received a BNT162b2 2024-2025 COVID-19 vaccine dose. VE against COVID-19-associated hospital admission was 41% (95% CI 2-64). Discussion: The 2024-2025 formulation of BNT162b2 COVID-19 vaccine provided significant protection, particularly for older adults, in mid-season estimates. This study is registered on clinicaltrials.gov as NCT06923137 .
Open Access2024-2025 BNT162b2 COVID-19 vaccine effectiveness in non-immunocompromised adults: mid-season estimates from vaccine registries in two states linked to administrative claims
Background: Data are limited on 2024-2025 BNT162b2 COVID-19 vaccine effectiveness (VE). Methods: Retrospective cohort study among non-immunocompromised adults from August 22, 2024 (“index”) to December 31, 2024, among residents of California or Louisiana continuously enrolled in health insurance plans reporting to HealthVerity for ≥1 year prior to index. Receipt of 2024-2025 BNT162b2 COVID-19 vaccine was defined using state vaccine registries with health insurance claims, using a time-varying exposure definition. VE against COVID-19-associated hospital admissions was estimated as (1-hazard ratio), using adjusted Cox proportional hazards models with 95% confidence intervals (CI). Results: Overall, 6,900,361 individuals met selection criteria for the study. By the end of follow-up (median 4.4 months), 325,362 (4.7%) had received a BNT162b2 2024-2025 COVID-19 vaccine dose. VE against COVID-19-associated hospital admission was 41% (95% CI 2-64). Discussion: The 2024-2025 formulation of BNT162b2 COVID-19 vaccine provided significant protection, particularly for older adults, in mid-season estimates. This study is registered on clinicaltrials.gov as NCT06923137 .
- Open Access
- 21 December 2020
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 205 (4) , 1133-1138
Does Pollen Trigger Urological Chronic Pelvic Pain Syndrome Flares? A Case-Crossover Analysis in the Multidisciplinary Approach to the Study of Chronic Pelvic Pain Research Network
Purpose:To determine whether pollen triggers urologic chronic pelvic pain syndrome (UCPPS) flares.Materials and Methods:We assessed flare status every two weeks for one year as part of the Multidis...
- 21 December 2020
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 205 (4) , 1133-1138
Open AccessDoes Pollen Trigger Urological Chronic Pelvic Pain Syndrome Flares? A Case-Crossover Analysis in the Multidisciplinary Approach to the Study of Chronic Pelvic Pain Research Network
Purpose:To determine whether pollen triggers urologic chronic pelvic pain syndrome (UCPPS) flares.Materials and Methods:We assessed flare status every two weeks for one year as part of the Multidis...